Biotech - Latest News and breaking headlines - Benzinga

Biotech

Apellis Valuation Ignores Empaveli Potential, Says Analyst

Apellis Valuation Ignores Empaveli Potential, Says Analyst

Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle

Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle

Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion

Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion

Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle

Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle

Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion

Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain

FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

Biotech Recent News

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritten offering of common stock.

Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface

Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface

FDA is reviewing AXIOS stent delivery issues after Boston Scientific reported injuries and deaths, urging facilities to stop use and remove affected devices.

Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences

Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences

Harbour BioMed exercises its warrant to buy Spruce Biosciences shares, raising its stake to about 3.8% as the companies work together on the SPR202 drug program.

Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma

Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or causing death by nearly half compared with Keytruda alone.

Valneva Steps Back From US Approval Bid For Chikungunya Vaccine

Valneva Steps Back From US Approval Bid For Chikungunya Vaccine

Valneva withdraws U.S. applications for its chikungunya vaccine Ixchiq after the FDA suspended the license and placed studies on hold following new reports of serious adverse events.

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious safety issues.

Bristol Myers, Microsoft Aim To Catch Lung Cancer Early With New AI Tool

Bristol Myers, Microsoft Aim To Catch Lung Cancer Early With New AI Tool

Bristol Myers Squibb partners with Microsoft to use AI imaging tools to detect lung cancer earlier and support radiologists.

GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough

GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough

GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.

Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action

Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action

The FDA delays its decision on Disc Medicine's rare disease drug bitopertin, raising review questions. Analysts say the setback is likely minor.

Venus Concept Stock Explodes Over 500% After Major Investor Takes Control

Venus Concept Stock Explodes Over 500% After Major Investor Takes Control

Venus Concept shares surge more than 500% as Madryn Asset discloses a 91% stake, driving heavy trading volume and renewed investor interest.

ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline

ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline

ImmunityBio stock jumps after strong trial updates in bladder cancer and lymphoma, with enrollment ahead of schedule and FDA filing plans outlined for Anktiva.

Profusa Stock Spikes As Lumee System Targets Research Market

Profusa Stock Spikes As Lumee System Targets Research Market

Profusa shares surged on heavy volume after launching its Lumee tissue oxygen monitoring system for research use, targeting contract research organizations and near-term service revenue.

Novo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data

Novo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data

U.K. drug regulator approves higher Wegovy dose as Novo Nordisk seeks U.S. and EU clearance. Trial data showed up to 21% average weight loss in adults with obesity.